MOTET · Metabolomics and Oncology: Transfer of European Technology
FP6 — Marie Curie Actions (Human Resources and Mobility)
- Duration
- 2005-03-10 → 2010-03-09
- EU contribution
- €910,534
- Participants
- 2
- Scheme
- TOK
Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.
Results in brief
Final Activity Report Summary - MOTET (Metabolomics and oncology: Transfer of European technology)
The MOTET project was designed to transfer technology from the established nuclear magnetic resonance (NMR) facility in Frankfurt to a newly launched facility in Birmingham. The development of NMR methods was targeted towards the development of metabolomics as a new field in the context of NMR spectroscopy. This included different aspects of NMR technology, from processing methods to dynamic nuclear polarisation. The overarching theme was set by applications in cancer biology, specifically metabolomics studies in acute myeloid leucaemia cell lines. NMR metabolomics was able to identify mechanisms of drugs in such cells, highlighting the role of reactive oxygen species for differentiation and apoptosis.
Data: CORDIS, © European Union
Project objective
The MOTET project combines two major strategic tasks:1.) Transfer of expertise from the Nuclear Magnetic Resonance (NMR) centre in Frankfurt, currently one of the largest NMR facilities in Europe, to the newly installed National NMR centres at the University of Birmingham. Such transfer will allow the development of strong links between the two partners, including exchange of post-doctoral research fellows.2.) Task 1 will be integrated in a combined scientific project that develops novel technologies to study the key molecular processes involved in the formation of cancer.Two approaches will be pursued: Firstly, direct interactions between a protein involved in cancer formation and selected inhibitors (with potential chemo-preventive value) will be investigated using well-established biological and NMR technologies, of which Frankfurt is a world leader. Secondly, NMR-based metabolomics will be developed as a new technique to characterise the metabolic response of living cells to several protein inhibitors, in particular to assess their ability to halt cancer progression with minimal metabolic side effects. The combined research will necessitate the development of new NMR techniques and software for metabolic profiling.
Original text from CORDIS.
Participants
- UNIVERSITY OF BIRMINGHAM · BIRMINGHAMCoordinatorUnited Kingdom
- JOHANN WOLFGANG GOETHE-UNIVERSITAT · FRANKFURT/MAINCity levelGermany
Links
Data: CORDIS, © European Union